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Background: Cardiovascular com-
plications remain the main cause of 
mortality in patients with chronic kid-
ney disease (CKD). Adiponectin is an 
adipose tissue-derived protein that car-
ries important cardioprotective prop-
erties. We aimed at investigating the 
determinants of adiponectin levels in 
CKD patients. Methods: This prospec-
tive observational study included 98 
CKD patients [glomerular filtration rate 
(GFR) 36.1+-14.4 ml/min, 56.5+-10.4 
y, 63% male, 31% diabetics, and body 
mass index (BMI) 27.1+-5.2 kg/m2]. 
Evaluation of adiponectin (imunoenzi-
matic assay), laboratory parameters, 
nutritional status (subjective global 
assessment), total body fat (dual x-ray 
energy absorptiometry), and visceral 
and subcutaneous abdominal fat (com-
puted tomography) was performed at 
baseline and after 12 months. Results: 
Adiponectin correlated with GFR (r = 
-0.45; p < 0.001), proteinuria (r = 0.21; 
p = 0.04), BMI (r = -0.33; p < 0.01), and 
visceral fat (r = -0.49; p < 0.001). In the 
linear regression analysis, the determi-
nants of adiponectin levels were sex (fe-
male β = 3.8; p < 0.01), age (β = 0.14; p 
= 0.03), GFR (β = -0.15; p < 0.01) and 
visceral fat (β = -0.04; p < 0.001) (R2 
= 0.41). After 12 months, a progression 
of the disease was evidenced by the re-
duction of GFR (-1.6+-6.3 ml/min; p = 
0.01) and increase of proteinuria (0.3+-
0.8 g/d; p < 0.01). An accumulation of 
visceral fat was observed, from 97+-73 
cm2 to 111+-82 cm2 (p < 0.001), with 
a concomitant reduction of adiponec-
tin concentration, from 27.6+-7.5 mg/l 
to 22.2+-11.6 mg/l (p < 0.001). Body 
weight, BMI, total body fat, and sub-
cutaneous abdominal fat remained un-
changed. After adjustments for the base-
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IntroductIon
Adiponectin is the most abundant pep-
tide produced by adipose tissue. This 
adipokine plays a regulatory role in in-
sulin sensitivity in addition to its impor-
tant anti-atherogenic and anti-inflam-
matory properties.1 In contrast to other 
adipokines, the expression and secretion 
of adiponectin in adipose tissue are in-
versely proportional to the amount of 
body fat.2
In patients with chronic kidney 
disease (CKD), the loss of renal function 
results in an increase of adiponectin 
concentrations. Yilmaz et al.3 showed 
that adiponectin accumulates gradually 
as the glomerular filtration rate decreases. 
In fact, several studies have consistently 
shown that the serum concentration 
of adiponectin significantly increases 
in CKD patients.4,5 However, in spite 
of the cardioprotective properties 
attributed to adiponectin, cardiovascular 
complications remain the main cause of 
line determinants of adiponectin, the in-
crease in visceral fat was independently 
associated with overtime decrease in 
adiponectin levels (β = -0.04; p = 0.025; 
R2 = 0.21). Conclusion: Age, sex, renal 
function and visceral fat were indepen-
dently associated with adiponectin lev-
els in nondialyzed CKD patients. How-
ever, variation in visceral fat was the 
only predictor of variation in adiponec-
tin levels over 12 months.
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mortality in this population, which are responsible 
for more than 50% of deaths.6 Therefore, 
investigating the determinants of adiponectin levels 
in CKD patients is important to understand the 
controversial relationship between this adipokine 
and mortality, which is extremely high from the very 
early stages of CKD.
The present study assessed the determinants of 
adiponectin levels and their changes over a period of 12 
months in patients in the non-dialysis phase of CKD.
Methods
Patients
This 12-month observational prospective study 
included 98 CKD patients in the non-dialysis phase 
monitored at a conservative treatment outpatient 
clinic. The exclusion criteria for the study were as 
follows: age < 18 years, amputation of limbs, ascites, 
hepatitis, presence of malignant diseases, and use of 
immunosuppressants and/or glucocorticoids. All 
patients were instructed to routinely consume a diet 
including 0.6-0.8 g/kg/day of proteins and 30-35 
kcal/kg/day, according to the recommendations of 
the Kidney Disease Outcomes Initiative (K-DOQI) 
practice guidelines.7
The study was approved by the Research Ethics 
Committee of the University, and informed consent 
was obtained from all the study participants.
labOratOry tests
The following laboratory parameters were analyzed 
from serum samples taken after 12 hours of fasting: 
creatinine, urea, glucose, albumin (bromocresol 
green), and high sensitivity C-reactive protein 
(immunochemiluminescence) levels. Adiponectin 
concentrations were determined by the enzyme-
linked immunosorbent assay (ELISA) method 
(Linco® Research, St. Charles, MO, USA) from 
serum samples stored at -70ºC. Proteinuria was 
measured from 24-hour urine samples and the 
glomerular filtration rate was estimated by the 
simplified Modification of Diet in Renal Disease 
(MDRD) equation.8
nutritiOnal status and bOdy cOmPOsitiOn
The patients were weighed while wearing light 
clothes and no shoes, by using an electronic scale 
(Filizola, SP, Brazil). The body mass index (BMI) 
was calculated as weight divided by the square of 
the height (kg/m2). A 7-point subjective global 
assessment (SGA) was used to assess the nutritional 
status.9 Total body fat was assessed using dual-
energy X-ray absorptiometry (Lunar Radiation 
Corporation, Madison, WI, USA), and abdominal 
fat (visceral and subcutaneous) was measured using 
computed tomography at vertebrae L4-L5 (Helical 
Picker PQ 5000, Cleveland, OH, USA).
statistical analysis
The results have been expressed as mean and 
standard deviation, median and interquartile range, 
or ratios. For the comparative analyses, the paired 
or independent Student’s t tests were applied for 
normally distributed variables, and the Mann-
Whitney or Wilcoxon tests were used for non-
normally distributed variables. The chi-squared 
test was used for the comparison of categorical 
variables. Pearson’s correlation coefficient was used 
to assess the associations between the variables, 
given that the non-normally distributed variables 
were log transformed. Multiple linear regression 
analyses were conducted to verify the determinants 
of adiponectin concentrations and the factors 
independently associated with variations in their 
levels over a period of 12 months.
The variables with significant results in the 
simple correlation test or those that might influence 
adiponectin levels were included in the regression 
models. Values of p < 0.05 were considered 
statistically significant. The analyses were conducted 
using the Statistical Package for the Social Sciences 
(SPSS) program for Windows, version 16 (SPSS Inc., 
Chicago, IL, USA).
results
crOss-sectiOnal analysis
The patient age varied from 28-79 years (56.5 ± 10.4 
years), the majority of the cohort were men (63%), 
and 31% of the patients had diabetes. The causes 
of CKD were hypertensive nephrosclerosis (27%), 
diabetic nephropathy (23%), tubulointerstitial 
nephropathy (12%), glomerulonephritis (8%), 
unspecified (7%), and others (22%). C-reactive 
protein levels indicative of inflammatory status (> 
0.50 mg/dL) were present in 35% of the patients, 
and levels indicative of cardiovascular risk (> 0.11 
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mg/dL) were noted in 78% of the patients. Most 
patients (79%) were eutrophic according to the 
subjective global assessment. BMI values of ≥ 25 
kg/m2 were observed in 60% of the patients, of 
whom 46% presented values that were ≥ 30 kg/m2. 
Only 3 patients had a BMI < 18.5 kg/m2. The main 
nutritional and laboratory characteristics are listed 
in Table 1.
tAble 1 characteristics Of the Patients in the  
 beginning Of the study PeriOd and after 
 12 mOnths (n = 98)
Beginning 12 months p
Glomerular 
filtration rate (mL/
min)
36.1 ± 14.4 34.5 ± 16.6 0.01
Serum creatinine 
(mg/dL)
2.1 ± 0.7 2.3 ± 1.0 < 0.001
Proteinuria (g/day) 1.1 ± 0.1 1.5 ± 0.2 0.002
C-reactive protein 
(mg/dL)
0.28 
(0.12−0.70)
0.25 
(0.08−0.74)
0.02
Adiponectin 
(mg/L)
27.6 ± 7.5 22.2 ± 11.6 < 0.001
Body mass index 
(kg/m2)
27.3 ± 5.1 27.2 ± 5.1 0.55
Total body fat (kg) 20.8 ± 9.2 21.2 ± 9.6 0.20
Total abdominal 
fat (cm2)
281 ± 147 288 ± 149 0.20
Visceral 
abdominal fat 
(cm2)
97 ± 73 111 ± 82 < 0.001
Subcutaneous 
abdominal fat 
(cm2)
184 ± 103 178 ± 98 0.15
Mean ± standard deviation or median and interquartile range; 
paired Student’s t-test.
Figure 1. Correlations between adiponectin and the glomerular 
filtration rate (A) and visceral fat (B).
glomerular filtration rate and visceral fat are shown 
in Figure 1A-B, respectively. The results of the linear 
regression model that more accurately described 
the determinants of adiponectin concentrations 
in the beginning of the study is shown in Table 2. 
Inflammation, nutritional status, and the presence of 
diabetes were not associated with adiponectin levels 
in these patients.
Adiponectin levels were higher in women than 
in men (31 ± 6.6 mg/L vs. 25.6 ± 7.2 mg/L, p < 
0.001). Women showed higher body fat percentages 
(38.4% ± 9.3% vs. 25% ± 6.8%, p < 0.001) and 
had more subcutaneous abdominal fat (234 ± 133 
cm2 vs. 155 ± 66 cm2, p = 0.002), while showing less 
visceral body fat (69 ± 61 cm2 vs. 113 ± 75 cm2, p = 
0.002) than men. Adiponectin levels were inversely 
correlated with BMI (r = -0.33, p < 0.01), visceral 
fat (r = -0.49, p < 0.001), and glomerular filtration 
rate (r = -0.45, p < 0.001) and were positively 
correlated with serum creatinine levels (r = 0.31, p 
= 0.002) and proteinuria (r = 0.21, p = 0.04). The 
correlations between adiponectin levels and the 
PrOsPective analysis
The characteristics of the patients in the beginning of 
the study and after 12 months are shown in Table 1. 
During the monitoring period, CKD progression was 
evidenced by a decrease in the glomerular filtration 
rate and an increase in serum creatinine level and 
proteinuria. An accumulation of visceral fat and 
the concurrent reduction of adiponectin levels 
were observed in both men and women. Weight, 
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For several years, it was believed that adipose 
tissue played a passive role in body energy 
homeostasis, being responsible for storing excess 
energy as triglycerides and releasing fatty acids for 
use as needed. The discovery of adipose tissue as a 
source of leptin hormone in 1994 initiated a new 
era of research, focusing on the endocrine role of 
adipose cells.10 Currently, adipose tissue is known to 
communicate with other tissues, organs, and systems 
through the synthesis and secretion of a collection 
of molecules referred to as adipokines, which 
have important biological activities.11 Among the 
adipokines, adiponectin has increasingly attracted 
attention in studies of CKD patients, as this protein 
plays a protective role in atherosclerotic processes by 
inhibiting the adhesion of monocytes to the vascular 
endothelium.12
However, in the presence of renal failure, 
which results in adiponectin accumulation, its role 
becomes even more complex, which translates into 
controversial findings in the literature regarding 
the true effects of adiponectin in CKD patients.13-15 
While some researchers support the protective role 
of adiponectin,16,17 others do not corroborate such a 
concept.18,19 Furthermore, the literature suggests that, 
among low, medium-, and high-molecular-weight 
adiponectin, the protective effect of this adipokine 
appears to be linked to its higher molecular weight 
fraction.20,21 This finding indicates the need for future 
investigations regarding the different molecular 
weights of adiponectin in the CKD population.
Although adiponectin synthesis occurs exclusively 
in adipose tissue, it is inversely related to total body 
fat.2 In the present study, an inverse correlation was 
observed between adiponectin level and BMI and 
visceral fat. It is believed that the cytokine tumor 
necrosis factor-alpha (TNF-α), which is upregulated 
if there is excess fat, inhibits the production of 
adiponectin by adipose tissue.1 However, in spite of 
the recent understanding of some of the physiological 
aspects of adipokines, the exact mechanisms involved 
in the production of adiponectin by adipocytes 
remain under investigation to date.
As a secretory organ, adipose tissue shows 
distinct peculiarities, beginning with its structural 
constitution. Adipose tissue comprises different 
cells, including mature adipocytes, preadipocytes, 
fibroblasts, and macrophages, which may participate 
tAble 3 determinants Of adiPOnectin level variatiOn  
 Over 12 mOnths (n = 98, r2 = 0.21)
Coefficient p
95% 
confidence 
interval
Sex (female) 2.2 0.14 -0.7 to 5.2
Age (years) 0.01 0.92 -0.13 to 0.15
Glomerular 
filtration rate 
(mL/min)
-0.10 0.046 -0.19 to -0.002
Visceral fat (cm2) -0.02 0.039 -0.04 to -0.001
∆ Glomerular 
filtration rate 
(mL/min)
-0.01 0.89 -0.22 to 0.19
∆ Visceral fat 
(cm2)
-0.04 0.025 -0.07 to -0.01
Constant -2.91 0.61 -14.2 to 8.4
Multiple linear regression analysis.
BMI, total body fat, and subcutaneous abdominal 
fat were unchanged in this period. The correlation 
coefficient (r) between the variations of adiponectin 
and visceral fat was -0.20 (p = 0.05). Changes in 
adiponectin levels were not correlated with the 
renal function parameters. With adjustment for 
the adiponectin determinants, only the changes in 
visceral fat were independently associated with the 
changes in adiponectin levels (Table 3).
tAble 2 determinants Of adiPOnectin levels in the 
 beginning Of the study (n = 98, r2 = 0.41)
Coefficient p
95% 
confidence 
interval
Sex (female) 3.8 0.007 1.1 to 6.6
Age (years) 0.14 0.032 0.01 to 0.27
Glomerular 
filtration rate 
(mL/min)
-0.15 0.001 -0.24 to -0.06
Visceral fat (cm2) -0.04 < 0.001 -0.06 to -0.02
Constant 23.6 < 0.001 13.0 to 34.2
Multiple linear regression analysis.
dIscussIon
The present study demonstrated that sex, age, renal 
function, and visceral fat were the determinants 
of adiponectin levels in CKD patients in the non-
dialysis phase, and the variation in visceral fat was 
a predictor of variation in adiponectin levels over a 
period of 12 months.
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differently in the secretory function. Additionally, 
adipose tissue exhibits a wide and varied organic 
distribution, which does not always seem to be 
linked.22
Finally, the metabolic capacity of the adipose 
tissue may vary due to its location, either visceral 
or subcutaneous, which may contribute more or 
less intensely to the secretion of adipokines.23 It 
is postulated that visceral fat secretes between 
2-3 times more pro-inflammatory cytokines than 
subcutaneous fat.24 Recent studies have shown that 
the expression of pro-inflammatory cytokines25,26 
and the infiltration of immunocompetent cells26 
are accentuated more in the subcutaneous and 
visceral adipose tissue of CKD patients than in 
healthy individuals. Teplan et al.27 showed that the 
expression levels of TNF-α mRNA, CD68 antigen, 
monocyte chemotactic protein-1, and adiponectin 
receptor-1 increase in the visceral fat of CKD patients, 
particularly in those who are obese. Furthermore, 
the authors showed that the expression of cytokines 
was significantly higher in the visceral fat compared 
to the subcutaneous fat.
Therefore, although the contribution of adipose 
tissue to systemic inflammation has yet to be 
fully elucidated,28 it is possible to assume that a 
mechanism involving inflammation is the most 
plausible explanation for the increase in visceral fat 
as the main determinant of the circulating levels of 
adiponectin observed in the present study.
The findings regarding visceral fat in the 
population with CKD using gold standard methods 
such as computed tomography or magnetic 
resonance imaging are based on association 
studies.29-34 Odamaki et al.31 showed that patients 
undergoing hemodialysis showed a larger area of 
visceral fat, as measured by computed tomography, 
than healthy individuals. Furthermore, researchers 
found that excess visceral fat is linked to changes 
in lipid profile. These associations were confirmed 
by other researchers who have also shown a direct 
link between visceral fat and the prevalence of 
carotid atherosclerosis in hemodialysis patients.32,33 
Gohda et al.34 showed that, in addition to being 
directly linked to insulin resistance, visceral fat 
was closely related to the presence of inflammation 
in hemodialysis patients, as visceral fat was an 
independent determinant of C-reactive protein levels 
in these patients. A recent study with hemodialysis 
patients showed that visceral fat is the most 
important determinant of high-molecular-weight 
adiponectin concentrations.35
A spontaneous accumulation of visceral fat has 
been shown in the few prospective studies involving 
non-dialysis phase patients36 and patients undergoing 
peritoneal dialysis.37,38 However, the association 
between visceral fat changes and cardiometabolic 
marker changes was not assessed in these studies. 
To our knowledge, the present study is the first 
to demonstrate the association between visceral 
fat changes and variations in adiponectin levels in 
the CKD population. The results of this work can 
contribute to a better understanding of the missing 
link between abdominal obesity and cardiovascular 
complications in patients with CKD.
This study has a limitation with regard to 
sample size, which was relatively small. However, 
this is a representative sample of the CKD 
population in the non-dialysis phase in terms of age, 
sex distribution, proportion of diabetic patients, 
and nutritional status. The advantage of the 
current study is the prospective design and the use 
of adequate methodologies considered as reference 
standards.
In the present study, we concluded that age, 
sex, renal function, and visceral fat are important 
determinants of adiponectin levels in CKD patients in 
the non-dialysis phase. However, the accumulation of 
visceral fat over time is the predictor of adiponectin 
level reduction in these patients. The implications of 
this finding in terms of clinical outcomes, including 
cardiovascular events and mortality, need to be 
investigated further. Nevertheless, the results of 
this study emphasize the need for preventive and 
therapeutic measures regarding visceral obesity 
present in the initial stages of CKD.
references
 1. Meier U, Gressner AM. Endocrine regulation of energy 
metabolism: review of pathobiochemical and clinical 
chemical aspects of leptin, ghrelin, adiponectin, and 
resistin. Clin Chem 2004;50:1511-25.
 2. Arita Y, Kihara S, Ouchi N, Takahashi M, Maeda K, 
Miyagawa J, et al. Paradoxical decrease of an adipose-
specific protein, adiponectin, in obesity. Biochem 
Biophys Res Commun 1999;257:79-83.
34(3) -inglês AO.indb   263 16/11/2012   09:14:26
J Bras Nefrol 2012;34(3):259-265264
Variations in adiponectin levels in patients with chronic kidney disease: a prospective study of 12 months
 3. Yilmaz MI, Saglam M, Qureshi AR, Carrero JJ, Caglar 
K, Eyileten T, et al. Endothelial dysfunction in type-2 
diabetics with early diabetic nephropathy is associated 
with low circulating adiponectin. Nephrol Dial 
Transplant 2008;23:1621-7.
 4. Ramos LF, Shintani A, Himmelfarb J, Ikizler TA. 
Determinants of plasma adiponectin levels in nondiabetic 
subjects with moderate to severe chronic kidney disease. 
J Ren Nutr 2009;19:197-203.
 5. Shen YY, Charlesworth JA, Kelly JJ, Loi KW, Peake PW. 
Up-regulation of adiponectin, its isoforms and receptors 
in end-stage kidney disease. Nephrol Dial Transplant 
2007;22:171-8.
 6. Collins AJ, Kasiske B, Herzog C, Chavers B, Foley R, 
Gilbertson D, et al.; United States Renal Data Group. 
Excerpts from the United States Renal Data System 2004 
annual data report: atlas of end-stage renal disease in the 
United States. Am J Kidney Dis 2005;45:A5-7,S1-280.
 7. Clinical practice guidelines for nutrition in chronic renal 
failure. K/DOQI, National KidneyFoundation. Am J 
Kidney Dis 2000;35:S1-140.
 8. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth 
D. A more accurate method to estimate glomerular 
filtration rate from serum creatinine: a new prediction 
equation. Modification of Diet in Renal Disease Study 
Group. Ann Intern Med 1999;130:61-70.
 9. Adequacy of dialysis and nutrition in continuous 
peritoneal dialysis: association with clinical outcomes. 
Canada-USA (CANUSA) Peritoneal Dialysis Study 
Group. J Am Soc Nephrol 1996;7:198-207.
10. Zhang Y, Proenca R, Maffei M, Barone M, Leopold L, 
Friedman JM. Positional cloning of the mouse obese gene 
and its human homologue. Nature 1994;372:425-32.
11. Kershaw EE, Flier JS. Adipose tissue as an endocrine 
organ. J Clin Endocrinol Metab 2004;89:2548-56.
12. Zoccali C, Tripepi G, Cambareri F, Catalano F, 
Finocchiaro P, Cutrupi S, et al. Adipose tissue cytokines, 
insulin sensitivity, inflammation, and cardiovascular 
outcomes in end-stage renal disease patients. J Ren Nutr 
2005;15:125-30.
13. Guebre-Egziabher F, Drai J, Fouque D. Adiponectin and 
chronic kidney disease. J Ren Nutr 2007;17:9-12.
14. Park SH, Carrero JJ, Lindholm B, Stenvinkel P. 
Adiponectin in chronic kidney disease has an opposite 
impact on protein-energy wasting and cardiovascular 
risk: two sides of the same coin. Clin Nephrol 
2009;72:87-96.
15. Carrero JJ, Cordeiro AC, Lindholm B, Stenvinkel P. The 
emerging pleiotrophic role of adipokines in the uremic 
phenotype. Curr Opin Nephrol Hypertens 2010;19:37-42.
16. Zoccali C, Malamaci F, Tripepi G, Benedetto FA, Cutrupi 
S, Parlongo S, et al. Adiponectin, metabolic risk factors, 
and cardiovascular events among patients with end-
stage renal disease. J Am Soc Nephrol 2002;13:134-41.
17. Rao M, Li L, Tighiouart H, Jaber BL, Pereira BJ, 
Balakrishnan VS; HEMO Study Group. Plasma 
adiponectin levels and clinical outcomes among 
haemodialysis patients. Nephrol Dial Transplant 
2008;23:2619-28.
18. Menon V, Li L, Wang X, Greene T, Balakrishnan 
V, Madero M, et al. Adiponectin and mortality in 
patients with chronic kidney disease. J Am Soc Nephrol 
2006;17:2599-606.
19. Ohashi N, Kato A, Misaki T, Sakakima M, Fujigaki Y, 
Yamamoto T, et al. Association of serum adiponectin 
levels with all-cause mortality in hemodialysis patients. 
Intern Med 2008;47:485-91.
20. Iwasa Y, Otsubo S, Ishizuka T, Uchida K, Nitta K. 
Influence of serum high-molecular-weight and total 
adiponectin on arteriosclerosis in IgA nephropathy 
patients. Nephron Clin Pract 2008;108:c226-32.
21. Tomizawa A, Hattori Y, Kasai K, Nakano Y. 
Adiponectin induces NF-kappaB activation that leads to 
suppression of cytokine-induced NF-kappaB activation 
in vascular endothelial cells: globular adiponectin vs. 
high molecular weight adiponectin. Diab Vasc Dis Res 
2008;5:123-7.
22. Guimarães DED, Sardinha FLC, Mizurini DM, Carmo 
MGT Adipokines: a new view of adipose tissue. Rev 
Nutr 2007;20:549-59.
23. Dusserre E, Moulin P, Vidal H. Differences in mRNA 
expression of the proteins secreted by the adipocytes 
in human subcutaneous and visceral adipose tissue. 
Biochim Biophys Acta 2000;1500:88-96.
24. Fried SK, Bunkin DA, Greenberg AS. Omental and 
subcutaneous adipose tissues of obese subjects release 
interleukin-6: depot difference and regulation by 
glucocorticoid. J Clin Endocrinol Metab 1998;83:847-50.
25. Witasp A, Carrero JJ, Heimbürger O, Lindholm B, 
Hammarqvist F, Stenvinkel P, et al. Increased expression 
of pro-inflammatory genes in abdominal subcutaneous 
fat in advanced chronic kidney disease patients. J Intern 
Med 2011;269:410-9.
26. Roubicek T, Bartlova M, Krajickova J, Haluzikova D, 
Mraz M, Lacinova Z, et al. Increased production of 
proinflammatory cytokines in adipose tissue of patients 
with end-stage renal disease. Nutrition 2009;25:762-8.
27. Teplan V Jr, Vyhnánek F, Gürlich R, Haluzík M, Racek 
J, Vyhnankova I, et al. Increased proinflammatory 
cytokine production in adipose tissue of obese patients 
with chronic kidney disease. Wien Klin Wochenschr 
2010;122:466-73.
28. Matsuzawa Y. Establishment of a concept of visceral fat 
syndrome and discovery of adiponectin. Proc Jpn Acad 
Ser B Phys Biol Sci 2010;86:131-41.
29. Kaysen GA, Kotanko P, Zhu F, Sarkar SR, Heymsfield 
SB, Kuhlmann MK, et al. Relationship between 
adiposity and cardiovascular risk factors in prevalent 
hemodialysis patients. J Ren Nutr 2009;19:357-64.
30. Sanches FM, Avesani CM, Kamimura MA, Lemos MM, 
Axelsson J, Vasselai P, et al. Waist circumference and 
visceral fat in CKD: a cross-sectional study. Am J Kidney 
Dis 2008;52:66-73.
31. Odamaki M, Furuya R, Ohkawa S, Yoneyama T, 
Nishikino M, Hishida A, et al. Altered abdominal fat 
distribution and its association with the serum lipid 
profile in non-diabetic haemodialysis patients. Nephrol 
Dial Transplant 1999;14:2427-32.
34(3) -inglês AO.indb   264 16/11/2012   09:14:26
J Bras Nefrol 2012;34(3):259-265J Bras Nefrol 2012;34(3):259-265 265
Variations in adiponectin levels in patients with chronic kidney disease: a prospective study of 12 months
32. Yamauchi T, Kuno T, Takada H, Nagura Y, Kanmatsuse 
K, Takahashi S. The impact of visceral fat on multiple 
risk factors and carotid atherosclerosis in chronic 
haemodialysis patients. Nephrol Dial Transplant 
2003;18:1842-47.
33. Kato A, Ishida J, Endo Y, Takita T, Furuhashi M, 
Maruyama Y, et al. Association of abdominal visceral 
adiposity and thigh sarcopenia with changes of 
arteriosclerosis in haemodialysis patients. Nephrol Dial 
Transplant 2011;26:1967-76.
34. Gohda T, Gotoh H, Tanimoto M, Sato M, Io H, 
Kaneko K, et al. Relationship between abdominal fat 
accumulation and insulin resistance in hemodialysis 
patients. Hypertens Res 2008;31:83-8.
35. Tamei N, Ogawa T, Ishida H, Ando Y, Nitta K. 
Relationship of high-molecular-weight adiponectin 
levels to visceral fat accumulation in hemodialysis 
patients. Intern Med 2010;49:299-305.
36. Velludo CM, Kamimura MA, Sanches FM, Lemos MM, 
Canziani ME, Pupim LB, et al. Prospective evaluation 
of waist circumference and visceral adipose tissue in 
patients with chronic kidney disease. Am J Nephrol 
2010;31:104-9.
37. Fernström A, Hylander B, Moritz A, Jacobsson H, 
Rössner S. Increase of intra-abdominal fat in patients 
treated with continuous ambulatory peritoneal dialysis. 
Perit Dial Int 1998;18:166-171.
38. Choi SJ, Kim NR, Hong SA, Lee WB, Park MY, Kim JK, 
et al. Changes in body fat mass in patients after starting 
peritoneal dialysis. Perit Dial Int 2011;31:67-73.
34(3) -inglês AO.indb   265 16/11/2012   09:14:26
